A Study of Trastuzumab Deruxtecan for People with Brain Cancer


Full Title

Window of Opportunity Assessment of [fam-]Trastuzumab DERuxtecan-nxki (T-DXd) Brain Tumor Penetration and Efficacy (WOnDER-BT)


Researchers want to see how much the drug trastuzumab deruxtecan (T-DXd) can get into brain tumors. The people in this study have glioblastoma or cancer that spread to the brain from other parts of the body. They are scheduled to have brain tumor surgery. In addition, their tumors express (make) a protein called HER2, which boosts cancer cell growth. Researchers want to know if T-DXd may be an effective treatment for brain cancers that express the HER2 protein.

If you join this study, you will get T-DXd before you have brain tumor surgery. You may be able to continue getting T-DXd after surgery as well. T-DXd is given intravenously (by vein).

Who Can Join

To join this study, there are a few conditions. You must:

  • Have glioblastoma or metastatic brain cancer that expresses HER2.
  • Be scheduled to have brain surgery.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information or to see if you can join this study, please call Dr. Nelson Moss’ office at 212-639-7075.




Phase II (phase 2)

Disease Status

Newly Diagnosed & Relapsed/Refractory



ClinicalTrials.gov ID